Aquestive Therapeutics is trading 5% up now at $5.33, with biotech-sector momentum appearing to drive the move.
- Biotech ETF XBI rose 2.06% during regular trading, alongside broader positive sentiment supporting biotechnology shares.
- The stock extended its advance from the August 25 close of $5.08; no new company-specific announcement dated August 26 was identified.
- Investors may also be carrying forward optimism from completed Anaphylm studies and a planned Q3 2026 FDA resubmission.